Muscular dystrophies are characterized by weakness and wasting of skeletal muscle tissues and treating wasting muscle is one of the biggest issues in the neuromuscular field. Several drugs targeting the myostatin pathway have been used in clinical trials to increase muscle mass and function but so far, most drugs had no or limited effects in improving function in neuromuscular patients. In our study, the expression levels of different actors of the myostatin network were analysed at mRNA and protein levels in neuromuscular patients’ sera and skeletal muscle specimens.

Read More...

Leave a comment.

Your email address will not be published. Required fields are marked*

Andoird App
Loading...